Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: A prospective clinical trial by the German 5-FU toxicity study group

Journal of Clinical Oncology

Volumn 26, Issue 13, 2008, Pages 2131-2138

  Schwab, Matthias ^a   Zanger, Ulrich M ^a   Marx, Claudia ^a   Schaeffeler, Elke ^a   Klein, Kathrin ^a   Dippon, Jürgen ^a   Kerb, Reinhold ^a   Blievernicht, Julia ^a   Fischer, Joachim ^a   Hofmann, Ute ^a   Bokemeyer, Carsten ^a   Eichelbaum, Michel ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); VITAMIN B COMPLEX;

ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL TRIAL; COLON CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; ENHANCER REGION; FEMALE; GASTROINTESTINAL TUMOR; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HOMOZYGOSITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX; WORLD HEALTH ORGANIZATION; CHEMICALLY INDUCED DISORDER; DNA METHYLATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; GERMANY; HOMOZYGOTE; HOSPITALIZATION; PATIENT SELECTION; PROMOTER REGION; PROSPECTIVE STUDY; RISK; STATISTICAL MODEL;

ANTIMETABOLITES, ANTINEOPLASTIC; DIARRHEA; DIHYDROURACIL DEHYDROGENASE (NADP); DNA METHYLATION; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERMANY; HOMOZYGOTE; HUMANS; LEUCOVORIN; LEUKOPENIA; LOGISTIC MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUCOSITIS; ODDS RATIO; PATIENT SELECTION; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THYMIDYLATE SYNTHASE; VITAMIN B COMPLEX;

EID: 43749114271     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.10.4182     Document Type: Article

References (35)

1. Lamont EB, Schilsky RL: The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 5:2289-2296, 1999
2. Meyerhardt JA, Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med 352:476-487, 2005
3. Rich TA, Shepard RC, Mosley ST: Four decades of continuing innovation with fluorouracil: Current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22:2214-2232, 2004
4. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors - Meta-Analysis Group in Cancer. J Clin Oncol 16:3537-3541, 1998
5. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 7:2203-2206, 1987
6. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51, 1988
7. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253, 1994
8. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993
9. Fleming RA, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992
10. Okuda H, Nishiyama T, Ogura K, et al: Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos 25:270-273, 1997
11. Johnson MR, Wang K, Diasio RB: Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 8:768-774, 2002
12. Raida M, Schwabe W, Hausler P, et al: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res 7:2832-2839, 2001
13. Soong R, Diasio RB: Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 6:835-847, 2005
14. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al: Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14 1g>a mutation. Int J Cancer 101:253-258, 2002
15. Wei X, McLeod HL, McMurrough J, et al: Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98:610-615, 1996
16. Morel A, Boisdron-Celle M, Fey L, et al: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 5:2895-2904, 2006
17. Milano G, Etienne MC, Cassuto-Viguier E, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175, 1992
18. Port RE, Daniel B, Ding RW, et al: Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 48:277-281, 1991
19. Chansky K, Benedetti J, Macdonald JS: Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103:1165-1171, 2005
20. Sloan JA, Goldberg RM, Sargent DJ, et al: Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20:1491-1498, 2002
21. Robien K, Boynton A, Ulrich CM: Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6:673-689, 2005
22. Horie N, Aiba H, Oguro K, et al: Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197, 1995
23. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65-70, 2001
24. Adleff V, Hitre E, Koves I, et al: Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients. Int J Cancer 108:852-856, 2004
25. Lecomte T, Ferraz JM, Zinzindohoue F, et al: Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880-5888, 2004
26. Dotor E, Cuatrecases M, Martinez-Iniesta M, et al: Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 24:1603-1611, 2006
27. Jakobsen A, Nielsen JN, Gyldenkerne N, et al: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol 23:1365-1369, 2005
28. Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated metaanalysis. J Clin Oncol 22:3766-3775, 2004
29. Zhang ZG, Rustum YM: Pharmacologic rationale for fluoropyrimidine- leucovorin combination: Biochemical mechanisms. Semin Oncol 19:46-50, 1992
30. Cohen V, Panet-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611-1615, 2003
31. Etienne MC, Formento JL, Chazal M, et al: Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics 14: 785-792, 2004
32. Fischer J, Schwab M, Eichelbaum M, et al: Mutational analysis of the human dihydropyrimidine dehydrogenase gene by denaturing high-performance liquid chromatography. Genet Test 7:97-105, 2003
33. Harrell FE: Regression Modeling Strategies, with Applications to Linear Models, Survival Analysis and Logistic Regression. New York, NY, Springer, 2001
34. Mattison LK, Fourie J, Desmond RA, et al: Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12:5491-5495, 2006
35. Ezzeldin HH, Lee AM, Mattison LK, et al: Methylation of the DPYD promoter: An alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11: 8699-8705, 2005